Construction of a chromosome 17 transcriptome in serous ovarian cancer identifies differentially expressed genes

International Journal of Gynecological Cancer

Volumn 18, Issue 5, 2008, Pages 963-975

  Wojnarowicz, P M ^a   Breznan, A ^a   Arcand, S L ^b   Filali Mouhim, A ^c   Provencher, D M ^c,d   Mes Masson, A M ^c,d   Tonin, P N ^a,b,e  

^a MCGILL UNIVERSITY   (Canada)

^b RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^c CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^d UNIVERSITÉ DE MONTRÉAL   (Canada)

^e MONTREAL GENERAL HOSPITAL   (Canada)

Author keywords

Chromosome 17; Expression microarray; Hypoxia; Ovarian cancer; Transcriptome

Indexed keywords

TRANSCRIPTOME;

ARTICLE; CELL CULTURE; CHROMOSOME 17; CONTROLLED STUDY; EPITHELIUM CELL; GENE EXPRESSION; GENE IDENTIFICATION; HUMAN; HUMAN CELL; MICROARRAY ANALYSIS; OVARY CANCER; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADULT; AGED; CHROMOSOMES, HUMAN, PAIR 17; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; RNA, MESSENGER; TUMOR CELLS, CULTURED;

EID: 51749111849     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1111/j.1525-1438.2007.01134.x     Document Type: Article

References (61)

1. Mitelman FJB, Mertens F. Mitelman Database of Chromosome Aberrations in Cancer. Available at http://cgap.nci.nih.gov/chromosomes/Mitelman. Accessed Feb 2007.
2. Dion F, Mes-Masson AM, Seymour RJ, Provencher D, Tonin PN. Allelotyping defines minimal imbalance at chromosomal region 17q25 in non-serous epithelial ovarian cancers. Oncogene 2000 19 : 1466 72.
3. Foulkes WD, Black DM, Stamp GW, Solomon E, Trowsdale J. Very frequent loss of heterozygosity throughout chromosome 17 in sporadic ovarian carcinoma. Int J Cancer 1993 54 : 220 5.
4. Pieretti M, Cavalieri C, Conway PS, Gallion HH, Powell DE, Turker MS. Genetic alterations distinguish different types of ovarian tumors. Int J Cancer 1995 64 : 434 40.
5. Galic V, Willner J, Wollan M et al. Common polymorphisms in TP53 and MDM2 and the relationship to TP53 mutations and clinical outcomes in women with ovarian and peritoneal carcinomas. Genes Chromosomes Cancer 2007 46 : 239 47.
6. Manderson EN, Presneau N, Provencher D, Mes-Masson AM, Tonin PN. Comparative analysis of loss of heterozygosity of specific chromosome 3, 13, 17, and X loci and TP53 mutations in human epithelial ovarian cancer. Mol Carcinog 2002 34 : 78 90.
7. Okamoto A, Sameshima Y, Yokoyama S et al. Frequent allelic losses and mutations of the p53 gene in human ovarian cancer. Cancer Res 1991 51 : 5171 6.
8. Shahin MS, Hughes JH, Sood AK, Buller RE. The prognostic significance of p53 tumor suppressor gene alterations in ovarian carcinoma. Cancer 2000 89 : 2006 17.
9. Swisher EM, Wollan M, Mahtani SM et al. Tumor-specific p53 sequences in blood and peritoneal fluid of women with epithelial ovarian cancer. Am J Obstet Gynecol 2005 193 : 662 7.
10. Tworek H, Peng R, Fetzer S et al. Mutation analysis of BRCA1, TP53, and KRAS2 in ovarian and related pelvic tumors. Cancer Genet Cytogenet 1999 112 : 105 18.
11. Berchuck A, Heron KA, Carney ME et al. Frequency of germline and somatic BRCA1 mutations in ovarian cancer. Clin Cancer Res 1998 4 : 2433 7.
12. Miki Y, Swensen J, Shattuck-Eidens D et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994 266 : 66 71.
13. Stratton JF, Gayther SA, Russell P et al. Contribution of BRCA1 mutations to ovarian cancer. N Engl J Med 1997 336 : 1125 30.
14. Tonin PN, Hudson TJ, Rodier F et al. Microarray analysis of gene expression mirrors the biology of an ovarian cancer model. Oncogene 2001 20 : 6617 26.
15. Cao Q, Abeysinghe H, Chow O et al. Suppression of tumorigenicity in human ovarian carcinoma cell line SKOV-3 by microcell-mediated transfer of chromosome 11. Cancer Genet Cytogenet 2001 129 : 131 7.
16. Godwin AK, Vanderveer L, Schultz DC et al. A common region of deletion on chromosome 17q in both sporadic and familial epithelial ovarian tumors distal to BRCA1. Am J Hum Genet 1994 55 : 666 77.
17. Jacobs IJ, Smith SA, Wiseman RW et al. A deletion unit on chromosome 17q in epithelial ovarian tumors distal to the familial breast/ovarian cancer locus. Cancer Res 1993 53 : 1218 21.
18. Jensen MR, Helin K. OVCA1: emerging as a bona fide tumor suppressor. Genes Dev 2004 18 : 245 8.
19. Kalikin LM, Bugeaud EM, Palmbos PL, Lyons RH Jr., Petty EM. Genomic characterization of human SEC14L1 splice variants within a 17q25 candidate tumor suppressor gene region and identification of an unrelated embedded expressed sequence tag. Mamm Genome 2001 12 : 925 9.
20. Kalikin LM, Frank TS, Svoboda-Newman SM, Wetzel JC, Cooney KA, Petty EM. A region of interstitial 17q25 allelic loss in ovarian tumors coincides with a defined region of loss in breast tumors. Oncogene 1997 14 : 1991 4.
21. Kalikin LM, Sims HL, Petty EM. Genomic and expression analyses of alternatively spliced transcripts of the MLL septin-like fusion gene (MSF) that map to a 17q25 region of loss in breast and ovarian tumors. Genomics 2000 63 : 165 72.
22. Leary JA, Doris CP, Boltz EM, Houghton CR, Kefford RF, Friedlander ML. Investigation of loss of heterozygosity at specific loci on chromosomes 3p, 6q, 11p, 17p and 17q in ovarian cancer. Int J Gynecol Cancer 1993 3 : 293 8.
23. Osaka M, Rowley JD, Zeleznik-Le NJ. MSF (MLL septin-like fusion), a fusion partner gene of MLL, in a therapy-related acute myeloid leukemia with a t(11;17)(q23;q25). Proc Natl Acad Sci U S A 1999 96 : 6428 33.
24. Presneau N, Dewar K, Forgetta V, Provencher D, Mes-Masson AM, Tonin PN. Loss of heterozygosity and transcriptome analyses of a 1.2 Mb candidate ovarian cancer tumor suppressor locus region at 17q25.1-q25.2. Mol Carcinog 2005 43 : 141 54.
25. Russell SE, McIlhatton MA, Burrows JF et al. Isolation and mapping of a human septin gene to a region on chromosome 17q, commonly deleted in sporadic epithelial ovarian tumors. Cancer Res 2000 60 : 4729 34.
26. Saretzki G, Hoffmann U, Rohlke P et al. Identification of allelic losses in benign, borderline, and invasive epithelial ovarian tumors and correlation with clinical outcome. Cancer 1997 80 : 1241 9.
27. Hirasawa A, Saito-Ohara F, Inoue J et al. Association of 17q21-q24 gain in ovarian clear cell adenocarcinomas with poor prognosis and identification of PPM1D and APPBP2 as likely amplification targets. Clin Cancer Res 2003 9 : 1995 2004.
28. Tapper J, Butzow R, Wahlstrom T, Seppala M, Knuutila S. Evidence for divergence of DNA copy number changes in serous, mucinous and endometrioid ovarian carcinomas. Br J Cancer 1997 75 : 1782 7.
29. Watanabe T, Imoto I, Kosugi Y et al. A novel amplification at 17q21-23 in ovarian cancer cell lines detected by comparative genomic hybridization. Gynecol Oncol 2001 81 : 172 7.
30. Afify AM, Werness BA, Mark HF. HER-2/neu oncogene amplification in stage I and stage III ovarian papillary serous carcinoma. Exp Mol Pathol 1999 66 : 163 9.
31. Lee CH, Huntsman DG, Cheang MC et al. Assessment of Her-1, Her-2, And Her-3 expression and Her-2 amplification in advanced stage ovarian carcinoma. Int J Gynecol Pathol 2005 24 : 147 52.
32. Presneau N, Mes-Masson AM, Ge B, Provencher D, Hudson TJ, Tonin PN. Patterns of expression of chromosome 17 genes in primary cultures of normal ovarian surface epithelia and epithelial ovarian cancer cell lines. Oncogene 2003 22 : 1568 79.
33. Provencher DM, Lounis H, Champoux L et al. Characterization of four novel epithelial ovarian cancer cell lines. In Vitro Cell Dev Biol Anim 2000 36 : 357 61.
34. Samouelian V, Maugard CM, Jolicoeur M et al. Chemosensitivity and radiosensitivity profiles of four new human epithelial ovarian cancer cell lines exhibiting genetic alterations in BRCA2, TGFbeta-RII, KRAS2, TP53 and/or CDNK2A. Cancer Chemother Pharmacol 2004 54 : 497 504.
35. Kruk PA, Maines-Bandiera SL, Auersperg N. A simplified method to culture human ovarian surface epithelium. Lab Invest 1990 63 : 132 6.
36. Lounis H, Provencher D, Godbout C, Fink D, Milot MJ, Mes-Masson AM. Primary cultures of normal and tumoral human ovarian epithelium: a powerful tool for basic molecular studies. Exp Cell Res 1994 215 : 303 9.
37. Novak JP, Sladek R, Hudson TJ. Characterization of variability in large-scale gene expression data: implications for study design. Genomics 2002 79 : 104 13.
38. Arcand SL, Mes-Masson AM, Provencher D, Hudson TJ, Tonin PN. Gene expression microarray analysis and genome databases facilitate the characterization of a chromosome 22 derived homogeneously staining region. Mol Carcinog 2004 41 : 17 38.
39. Zody MC, Garber M, Adams DJ et al. DNA sequence of human chromosome 17 and analysis of rearrangement in the human lineage. Nature 2006 440 : 1045 9.
40. Gentleman RC, Carey VJ, Bates DM et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol 2004 5 : R80.
41. Hochberg Y, Benjamini Y. More powerful procedures for multiple significance testing. Stat Med 1990 9 : 811 8.
42. Cody NA, Ouellet V, Manderson EN et al. Transfer of chromosome 3 fragments suppresses tumorigenicity of an ovarian cancer cell line monoallelic for chromosome 3p. Oncogene 2007 26 : 618 32.
43. Miracco C, Cosci E, Oliveri G et al. Protein and mRNA expression of autophagy gene Beclin 1 in human brain tumours. Int J Oncol 2007 30 : 429 36.
44. Schutyser E, Struyf S, Proost P et al. Identification of biologically active chemokine isoforms from ascitic fluid and elevated levels of CCL18/pulmonary and activation-regulated chemokine in ovarian carcinoma. J Biol Chem 2002 277 : 24584 93.
45. Soini Y, Talvensaari-Mattila A. Expression of claudins 1, 4, 5, and 7 in ovarian tumors of diverse types. Int J Gynecol Pathol 2006 25 : 330 5.
46. Bignotti E, Tassi RA, Calza S et al. Differential gene expression profiles between tumor biopsies and short-term primary cultures of ovarian serous carcinomas: identification of novel molecular biomarkers for early diagnosis and therapy. Gynecol Oncol 2006 103 : 405 16.
47. Ouellet V, Provencher DM, Maugard CM et al. Discrimination between serous low malignant potential and invasive epithelial ovarian tumors using molecular profiling. Oncogene 2005 24 : 4672 87.
48. Sica A, Wang JM, Colotta F et al. Monocyte chemotactic and activating factor gene expression induced in endothelial cells by IL-1 and tumor necrosis factor. J Immunol 1990 144 : 3034 8.
49. Arnold JM, Huggard PR, Cummings M, Ramm GA, Chenevix-Trench G. Reduced expression of chemokine (C-C motif) ligand-2 (CCL2) in ovarian adenocarcinoma. Br J Cancer 2005 92 : 2024 31.
50. Kulbe H, Thompson R, Wilson JL et al. The inflammatory cytokine tumor necrosis factor-alpha generates an autocrine tumor-promoting network in epithelial ovarian cancer cells. Cancer Res 2007 67 : 585 92.
51. Szlosarek PW, Grimshaw MJ, Kulbe H et al. Expression and regulation of tumor necrosis factor alpha in normal and malignant ovarian epithelium. Mol Cancer Ther 2006 5 : 382 90.
52. Milliken D, Scotton C, Raju S, Balkwill F, Wilson J. Analysis of chemokines and chemokine receptor expression in ovarian cancer ascites. Clin Cancer Res 2002 8 : 1108 14.
53. Drimal D, Drimal J, Drimal J Jr. The regulation of human adrenomedullin (AM) and tumor necrosis factor alpha (TNF-alpha) receptors on human epithelial carcinoma (HeLa) cells. The role of AM secretion in tumor cell sensitivity. Neoplasma 2006 53 : 144 9.
54. Klinger M, Freissmuth M, Nanoff C. Adenosine receptors: G protein-mediated signalling and the role of accessory proteins. Cell Signal 2002 14 : 99 108.
55. Sitkovsky MV, Lukashev D, Apasov S et al. Physiological control of immune response and inflammatory tissue damage by hypoxia-inducible factors and adenosine A2A receptors. Annu Rev Immunol 2004 22 : 657 82.
56. Raskovalova T, Huang X, Sitkovsky M, Zacharia LC, Jackson EK, Gorelik E. Gs protein-coupled adenosine receptor signaling and lytic function of activated NK cells. J Immunol 2005 175 : 4383 91.
57. Proikas-Cezanne T, Waddell S, Gaugel A, Frickey T, Lupas A, Nordheim A. WIPI-1alpha (WIPI49), a member of the novel 7-bladed WIPI protein family, is aberrantly expressed in human cancer and is linked to starvation-induced autophagy. Oncogene 2004 23 : 9314 25.
58. Pouyssegur J, Dayan F, Mazure NM. Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature 2006 441 : 437 43.
59. Edinger AL, Thompson CB. Defective autophagy leads to cancer. Cancer Cell 2003 4 : 422 4.
60. Halestrap AP, Price NT. The proton-linked monocarboxylate transporter (MCT) family: structure, function and regulation. Biochem J 1999 343 (Pt 2 281 99.
61. Ord JJ, Streeter EH, Roberts IS, Cranston D, Harris AL. Comparison of hypoxia transcriptome in vitro with in vivo gene expression in human bladder cancer. Br J Cancer 2005 93 : 346 54.